Toll-like receptor modulators: a patent review (2006 – 2010)

Identification of Novel Synthetic Toll-like Receptor 2 Agonists by High Throughput Screening

(2010) Yue Guan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

(2010) Taro Kawai et al.   NATURE IMMUNOLOGY

Targeting Toll-like receptors: emerging therapeutics?

(2010) Elizabeth J. Hennessy et al.   NATURE REVIEWS DRUG DISCOVERY

Molecular Modeling-Based Evaluation of hTLR10 and Identification of Potential Ligands in Toll-Like Receptor Signaling

(2010) Rajiv Gandhi Govindaraj et al.   PLoS One

Structure-Function Relationship of Cytoplasmic and Nuclear IκB Proteins: An In Silico Analysis

(2010) Balachandran Manavalan et al.   PLoS One

Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates

(2010) Kavita Tewari et al.   VACCINE

Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists

(2009) Jörg Vollmer et al.   ADVANCED DRUG DELIVERY REVIEWS

A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis

(2009) Ryan Ungaro et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Drugs targeting toll-like receptors

(2009) Jayalakshmi Krishnan et al.   ARCHIVES OF PHARMACAL RESEARCH

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

(2009) Jonathan W. Friedberg et al.   BRITISH JOURNAL OF HAEMATOLOGY

The antiviral activity of toll-like receptor 7 and 7/8 agonists

(2009) R.L. Miller et al.   DRUG NEWS & PERSPECTIVES

Emerging drugs for the treatment of ulcerative colitis

(2009) Luca Pastorelli et al.   EXPERT OPINION ON EMERGING DRUGS

Vaccine adjuvants: scientific challenges and strategic initiatives

(2009) Ali M Harandi et al.   Expert Review of Vaccines

Identification and characterization of oligonucleotides that inhibit Toll-like receptor 2-associated immune responses

(2009) Yi-Chung Chang et al.   FASEB JOURNAL

The potential use of toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents

(2009) Amani Makkouk et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Dendritic cells require a systemic type I interferon response to mature and induce CD4+Th1 immunity with poly IC as adjuvant

(2009) M. Paula Longhi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Morphological study on Mycobacterium bovis BCG Tokyo 172 cell wall skeleton (SMP-105)

(2009) Yuko Uenishi et al.   JOURNAL OF MICROBIOLOGICAL METHODS

The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex

(2009) Beom Seok Park et al.   NATURE

Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer

(2009) L. A. J. O'Neill et al.   PHARMACOLOGICAL REVIEWS

Toll-like receptor 2 dependent immunogenicity of glycoconjugate vaccines containing chemically derived zwitterionic polysaccharides

(2009) S. Gallorini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Innate immune sensing and activation of cell surface Toll-like receptors

(2009) Richard I. Tapping   SEMINARS IN IMMUNOLOGY

In vivo and in vitro adjuvant activities of the B subunit of Type IIb heat-labile enterotoxin (LT-IIb-B5) from Escherichia coli

(2009) Shuang Liang et al.   VACCINE

Ampligen: A potential toll-like 3 receptor adjuvant for immunotherapy of cancer

(2009) B. Jasani et al.   VACCINE

Paired Toll-like Receptor Agonists Enhance Vaccine Therapy through Induction of Interleukin-12

(2008) R. Zheng et al.   CANCER RESEARCH

Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors

(2008) Masashi Murata   CANCER SCIENCE

Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant

(2008) C. R. Casella et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

(2008) R. Dummer et al.   CLINICAL CANCER RESEARCH

Self-Adjuvanting Lipopeptide Vaccines

(2008) Peter Moyle et al.   CURRENT MEDICINAL CHEMISTRY

Bridging Innate Immunity and Myocardial Ischemia/Reperfusion Injury: The Search for Therapeutic Targets

(2008) Fatih Arslan et al.   CURRENT PHARMACEUTICAL DESIGN

Functional diversification of the toll-like receptor gene family

(2008) Austin L. Hughes et al.   IMMUNOGENETICS

TLR4-induced IFN-γ production increases TLR2 sensitivity and drives Gram-negative sepsis in mice

(2008) Stephan Spiller et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Characterization of bovine Toll-like receptor 8: Ligand specificity, signaling essential sites and dimerization

(2008) Jianzhong Zhu et al.   MOLECULAR IMMUNOLOGY

Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis

(2008) SA Broadley et al.   Multiple Sclerosis Journal

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

(2008) A M Krieg   ONCOGENE

Toll-like receptors and immune regulation: implications for cancer therapy

(2008) R-F Wang et al.   ONCOGENE

TLR7 and TLR8 as targets in cancer therapy

(2008) M P Schön et al.   ONCOGENE

An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models

(2008) L. G. Burdelya et al.   SCIENCE

Structural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA

(2008) L. Liu et al.   SCIENCE

Cathepsin K-Dependent Toll-Like Receptor 9 Signaling Revealed in Experimental Arthritis

(2008) M. Asagiri et al.   SCIENCE

Role of neutrophils in BCG immunotherapy for bladder cancer

(2008) Mark P. Simons et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

The PorB porin from commensal Neisseria lactamica induces Th1 and Th2 immune responses to ovalbumin in mice and is a potential immune adjuvant

(2008) Xiuping Liu et al.   VACCINE

Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia

(2008) Joachim Köchling et al.   VACCINE

Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids

(2007) Xinyan Liu et al.   ATHEROSCLEROSIS

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

(2007) James W. Huleatt et al.   VACCINE